A phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic adenocarcinoma
Phase 1
- Conditions
- nresectable locally advanced pancreatic adenocarcinoma
- Registration Number
- JPRN-UMIN000012254
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1.Active infection 2.Lung fibrosis or intestinal pneumonia detectable on chest X-ray and CT 3.Severe complication (heart disease, cirrhosis, diabetes) 4.Myocardial infarction within 3 months 5.Active synchronous or metachronous malignancy 6.Pregnant or lactation women, or women with known or suspected pregnancy 7.Symptomatic brain metastasis 8.history of severe drug allergy 9.Peripheral neuropathy 10.Patients who are judged inappropriate for the entry into the study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Response Rate, Overall Survival time, Palliative efficacy